Recipharm

How can you reduce development, bioequivalence and filing risk in a complex generic OSD programme? Developing a complex, poorly soluble generic product can bring formulation challenges together with bioequivalence and regulatory considerations. In our latest case study, we share how we supported our client by combining QbD-led formulation development, discriminatory dissolution, early regulatory alignment and a fit-for-purpose bioequivalence strategy to progress the product towards filing and commercialisation. Read the case study: https://lnkd.in/dK8QA5rR #GenericsDevelopment #QbD #OSDdevelopment

Will we see us at CDMO Live Americas 2026? On 20–21 October 2026, Andy Maitland and Harshul Batra, Ph.D will represent Recipharm at the Sheraton Boston, connecting with pharmaceutical and biotech leaders and discussing how Recipharm can provide one seamless path to market - from development to commercial manufacturing. If you are attending, visit us at booth A13 to discuss your development and manufacturing needs or reach ut to us and prearrange a meeting. Learn more and register: https://lnkd.in/eEQpwEv8 See you in Boston! #CDMOLive #Recipharm #CDMO #Pharma #Biotech

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 𝗢𝘂𝘁𝘀𝗼𝘂𝗿𝗰𝗲𝗱 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝘀 𝗽𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘀𝗲𝗿𝗶𝗲𝘀! During the session, one of our experts, Douglas Mogensen, will explore how integrated development and GMP manufacturing strategies can accelerate the journey from RNA therapeutic concept to clinic and commercialization. Attendees will gain insights into Recipharm's end-to-end capabilities spanning plasmid DNA, mRNA, circular RNA, lipid nanoparticle (LNP) formulation, sterile fill-finish, analytical development, and regulatory support within a unified manufacturing framework. The webinar will also highlight platform technologies for RNA process development, in vitro transcription optimization, advanced LNP delivery systems, and emerging gene-editing workflows. Through discussions on integrated supply chains and continuous manufacturing innovations, you'll discover how to reduce development risk, compress timelines, and enable scalable production of next-generation RNA medicines. Register Now: https://lnkd.in/gQNCieGT #mRNA #Biopharma #CDMO #Biotech #ManufacturingInnovation

How can science-led development help de-risk your OSD programme? Decisions made early in development can influence much more than the next milestone. Understanding the formulation and process from the outset can help identify technical risks earlier and guide decisions with robustness, scale-up and future manufacturing in mind. In our latest article, Balasubramaniam Jagdish, Vice President Formulation Development, explores why connecting formulation, analytical and technical expertise early matters, and shares a real development example involving a complex extended-release fixed-dose combination. Read the full article here: https://lnkd.in/ds4R-m-S

Discover how we worked with a pharmaceutical partner to transition from polystyrene to fully recyclable PET tray packaging for ampoules and vials, helping improve circularity while maintaining operational performance and regulatory requirements. Key outcomes: • 6.4 tons of polystyrene avoided annually • 12.8 tons CO₂ saved per year • Implemented within existing packaging operations Read the full case here: https://lnkd.in/dkxUmvPR

𝗧𝗵𝗲 𝗰𝗼𝘂𝗻𝘁𝗱𝗼𝘄𝗻 𝘁𝗼 𝗖𝗣𝗛𝗜 𝗠𝗶𝗹𝗮𝗻 𝗶𝘀 𝗼𝗻! In just a few weeks, the global pharma community will come together in Milan and the Recipharm team will be there. Our Business Development and Commercial teams, including Neil Jones, Andy Maitland, Jon Reed, Douglas Mogensen, Satish N., Michele Balacco, Antonio Lopez Folgueira, Rachel Maire, MBA, Leda Consonni, Kunal M., Ana Luísa Ferreira, Emil Lowenberg, Karthik Krishnan, Harshul Batra, Ph.D, Maria Riccius, Jhomar Marquez, Luís Raiado and Natalie Kazimierczak will be attending, together with many more colleagues from across Recipharm. If you’re looking for a partner who can support your journey from development through to commercial supply, CPHI is a great opportunity to start the conversation. 𝗢𝗡𝗘 𝗽𝗮𝗿𝘁𝗻𝗲𝗿. 𝗢𝗡𝗘 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝗽𝗮𝘁𝗵 𝗳𝗼𝗿𝘄𝗮𝗿𝗱. 𝗢𝗡𝗘 𝘀𝘁𝗲𝗽 𝗮𝗵𝗲𝗮𝗱. CPHI Milan takes place from 6–8 October 2026. You can find us in Hall 𝟲, 𝗕𝗼𝗼𝘁𝗵 𝟲𝗔𝟱𝟴. Our calendars are filling up, so reach out to your Recipharm contact to arrange a meeting. See you in Milan! #CPHI #CPHIMilan #Recipharm #CDMO #PharmaceuticalManufacturing #DrugDevelopment

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 𝗢𝘂𝘁𝘀𝗼𝘂𝗿𝗰𝗲𝗱 𝗣𝗵𝗮𝗿𝗺𝗮 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗵𝗼𝘄 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗮𝗿𝗲 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝗯𝗿𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗳𝗮𝘀𝘁𝗲𝗿! Douglas Mogensen will discuss the critical role of coordinated expertise across plasmid production, RNA synthesis, formulation, analytics, and GMP manufacturing, while showcasing the technologies and capabilities that support a seamless path from development through commercialization. You'll also gain insights into advanced LNP delivery systems, RNA process optimization, emerging gene-editing workflows, and strategies for reducing risk while accelerating timelines. Register today to learn how integrated platforms can support the scalable production of next-generation RNA medicines:  https://lnkd.in/gQNCieGT #mRNA #Biopharma #DrugDevelopment #GeneEditing #CDMO

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 𝗢𝘂𝘁𝘀𝗼𝘂𝗿𝗰𝗲𝗱 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝘀 𝗽𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘀𝗲𝗿𝗶𝗲𝘀! During the session, one of our experts, Douglas Mogensen, will explore how integrated development and GMP manufacturing strategies can accelerate the journey from RNA therapeutic concept to clinic and commercialization. Attendees will gain insights into Recipharm's end-to-end capabilities spanning plasmid DNA, mRNA, circular RNA, lipid nanoparticle (LNP) formulation, sterile fill-finish, analytical development, and regulatory support within a unified manufacturing framework. The webinar will also highlight platform technologies for RNA process development, in vitro transcription optimization, advanced LNP delivery systems, and emerging gene-editing workflows. Through discussions on integrated supply chains and continuous manufacturing innovations, you'll discover how to reduce development risk, compress timelines, and enable scalable production of next-generation RNA medicines. Register Now: https://lnkd.in/gQNCieGT #mRNA #Biopharma #CDMO #Biotech #ManufacturingInnovation

How can advanced deformulation help de-risk complex generic development? Understanding a reference product in detail can help inform formulation decisions, reduce unnecessary development iterations and reduce development uncertainty. Our new white paper explores how advanced deformulation and specialist analytical expertise support complex generic development, from reverse engineering and formulation development through to bioequivalence and filing readiness. We will also share practical examples of how our analytical experts have tackled complex excipient identification and quantification challenges. Read the white paper: https://lnkd.in/dfvkTk_x

𝗠𝗶𝗹𝗮𝗻, 𝗵𝗲𝗿𝗲 𝘄𝗲 𝗰𝗼𝗺𝗲! Preparations are well underway for 𝗖𝗣𝗛𝗜 𝗠𝗶𝗹𝗮𝗻, 𝘁𝗮𝗸𝗶𝗻𝗴 𝗽𝗹𝗮𝗰𝗲 𝗳𝗿𝗼𝗺 𝟲–𝟴 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟲. Whether you’re exploring a new formulation, planning your next development milestone or preparing for commercial supply - CPHI is the perfect place to start the conversation. The Recipharm team will be ready to discuss how we can support your project with the expertise, capabilities and partnership needed to move forward with confidence. 𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗶𝗻 𝗛𝗮𝗹𝗹 𝟲, 𝗕𝗼𝗼𝘁𝗵 𝟲𝗔𝟱𝟴, 𝗳𝗿𝗼𝗺 𝟲–𝟴 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟲. Our meeting calendars are already open, so if you’re attending CPHI, get in touch to arrange a meeting with us. https://lnkd.in/dk_KB9ag We look forward to meeting you in Milan! #CPHI #CPHIMilan #Recipharm #CDMO #Pharma #PharmaOutsourcing